Nuvectis Pharma, Inc. NVCT

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

We are a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. We seek to develop drug candidates in the precision medicine space, and our processes for selection and clinical development of drug candidates are based on scientific data into cancer-promoting factors, as well as our understanding of the clinical landscape and regulatory requirements.

We were incorporated in July 2020 under the laws of the State of Delaware under the name Centry Pharma, Inc., and changed our name to Nuvectis Pharma, Inc. in July 2021. Our office is located at 1 Bridge Plaza, 2nd Floor, Fort Lee, NJ 07024, and our telephone number is (201) 614-3150.

Last close 20.05 2026-10-23
Market cap $653.3M 2026-06-30 share count
52-week range 5.55 - 29.27

Valuation FY2025 figures against the last close

P/S—
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-1.32

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
R&D $18.2M$12.9M$15.4M$13.2M$9.5M—
SG&A $9.4M$6.9M$7.5M$6.0M$3.3M—
Operating income -$27.6M-$19.8M-$22.9M-$19.2M-$12.9M—
Net income -$26.4M-$19.0M-$22.3M-$19.1M-$12.9M—
EPS, basic -1.32-1.11-1.43-1.51-3.02—
EPS, diluted -1.32-1.11-1.43-1.51-3.02—
Shares, diluted (wtd. avg.) 21.8M17.1M15.6M12.7M4.3M—

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Cash and equivalents $31.6M$18.5M$19.1M$20.0M$5.7M—
Total current assets $31.7M$18.6M$19.2M$20.4M$5.8M—
Total assets $31.7M$18.6M$19.2M$20.4M$6.7M—
Accounts payable $6.3M$2.5M$2.8M$2.9M$1.1M—
Total current liabilities $13.3M$8.9M$7.0M$6.2M$2.4M—
Total liabilities $13.3M$8.9M$7.0M$6.2M$2.4M—
Retained earnings -$99.7M-$73.2M-$54.2M-$32.0M-$12.9M—
Total equity $18.4M$9.7M$12.2M$14.2M-$11.0M-$10.0K

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020
Operating cash flow -$16.0M-$12.2M-$16.0M-$13.6M-$9.5M—
Stock-based compensation $6.0M$4.9M$4.7M$1.7M$1.9M—
Investing cash flow —$0$0$0——
Financing cash flow $29.1M$11.7M$15.1M$27.8M$15.2M—

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-013044.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -30M -20M -10M 0 Net income, FY2021: -12.9M Net income, FY2022: -19.1M Net income, FY2023: -22.3M Net income, FY2024: -19M Net income, FY2025: -26.4M FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2020FY2021FY2022FY2023FY2024FY2025
Revenue — — — — — —
Gross profit — — — — — —
Net income — -$12.9M -$19.1M -$22.3M -$19.0M -$26.4M

Recent filings and events

  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Other event Item 8.01
  • Other event Item 8.01
  • Material agreement signed Item 1.01
  • Other event Item 8.01
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%